10 Best Peptides for Men Over 40 (2026): Benefits & Research

After 40, the hormonal landscape shifts dramatically for men. Growth hormone output drops 1–2% per year starting in your 30s. Testosterone declines at roughly 1% annually after 30. Recovery slows. Muscle comes off more easily than it goes on. Joint pain becomes a familiar companion. And libido — once automatic — requires more deliberate attention. The good news is that the best peptides for men over 40 directly address these specific physiological changes, working with your body’s own signaling systems to restore the hormonal and metabolic function that time erodes. Here are ten peptide and peptide-drug options for men navigating this chapter of life, with the evidence and regulatory status behind each.

Peptides for Men Over 40 at a Glance

The best-supported options for men over 40 depend on the goal: tesamorelin and the GLP-1 medicines have randomized-trial evidence and FDA approval for specific indications, while most other peptides on this list rest on small human studies or animal research. The table below compares all ten by mechanism, evidence level and current regulatory status (see the FDA Peptide Status Tracker for live updates).

PCAC votes are advisory: none of these peptides is on the 503A Bulks List until FDA completes notice-and-comment rulemaking, expected to run into 2027. Dosing, if any therapy is appropriate, is a decision for the prescribing clinician.

1. Sermorelin — For GH Restoration and Metabolic Health

Targets: GH decline, body composition, energy, sleep

Sermorelin is the most clinically established peptide for adult-onset growth hormone deficiency — a condition that affects the majority of men by their mid-40s, even if they don’t know it. As the first 29 amino acids of naturally occurring GHRH, Sermorelin stimulates the pituitary to release GH in a pulsatile, physiological pattern — not the supraphysiologic burst of synthetic HGH. This natural approach means the body’s feedback mechanisms remain intact, reducing the risk of side effects associated with exogenous GH. Men on Sermorelin typically report improved sleep quality within weeks, followed by progressive changes in body composition (more muscle, less visceral fat), improved energy, and cognitive clarity over a 3–6 month course. It is the ideal starting point for men experiencing the broad hormonal decline of midlife. For a clinician's view of how sermorelin fits alongside testosterone optimization, see ACT 2's guide to peptide therapy for andropause and midlife men.

2. CJC-1295 + Ipamorelin — The Workhorse Stack for Performance and Body Composition

Targets: GH output, fat loss, muscle preservation, sleep, recovery

If Sermorelin is the entry-level option, CJC-1295 + Ipamorelin is the performance-optimized upgrade. CJC-1295 is a more potent and longer-acting GHRH analogue, while Ipamorelin selectively amplifies GH pulses without the cortisol and prolactin side effects of older GHRPs. Together, they produce GH output significantly higher than either alone, driving meaningful changes in body composition — increased lean mass, reduced visceral fat, improved workout recovery, and deeper sleep. For men over 40 who are still training hard and want to preserve or build muscle while shedding fat, this stack is often the most effective pharmacological tool available within the bounds of safe, supervised peptide therapy. See [our CJC-1295 + Ipamorelin guide] for complete protocol guidance.

3. BPC-157 — For Joint Health and Injury Recovery

Targets: Joint pain, tendon and ligament repair, gut health, inflammation

By your 40s, the accumulation of hard training, previous injuries, and the natural loss of collagen becomes evident in chronically sore joints, slow-healing tendons, and nagging connective tissue problems that simply won’t resolve the way they used to. BPC-157 is one of the most remarkable healing peptides known, with documented ability to accelerate tendon, ligament, and muscle healing in animal models — with emerging human clinical data supporting these effects. It works through multiple mechanisms: promoting angiogenesis in healing tissue, upregulating nitric oxide synthase, modulating growth factor receptors, and reducing inflammatory signaling. For men who want to maintain an active lifestyle without joint pain holding them back, BPC-157 may be the single most impactful peptide they can add. Many report significant improvement in chronic injuries within 4–8 weeks of use.

4. PT-141 (Bremelanotide) — For Libido and Sexual Function

Targets: Sexual desire, erectile function, arousal (both physical and psychological)

PT-141 is the only peptide with an FDA-approved indication for sexual dysfunction — specifically hypoactive sexual desire disorder (HSDD) in premenopausal women, approved as Vyleesi; use in men is off-label. It works through a fundamentally different mechanism than PDE5 inhibitors like sildenafil: rather than acting on blood vessel dilation, PT-141 acts centrally on melanocortin receptors in the hypothalamus, directly activating the brain circuits responsible for sexual desire and arousal. This means it addresses the psychological/neurological component of libido loss, not just the plumbing. For men over 40 experiencing declining interest in sex (not just performance issues), PT-141 can be genuinely transformative — often producing noticeable effects within a few hours of administration. It is available through licensed compounding pharmacies with a prescription and may be used on an as-needed basis.

5. Tesamorelin — For Visceral Fat

Targets: Visceral (abdominal) fat, liver fat, GH axis

Tesamorelin is a stabilized GHRH analogue and the only GH-axis peptide on this list with an active FDA approval: it is marketed as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. In a phase 3 randomized trial, visceral fat fell by 15.2% over 26 weeks with tesamorelin versus a 5.0% increase with placebo. The pivotal trials enrolled people with HIV, so use for age-related central adiposity in otherwise healthy men is off-label and less studied. Prescribers typically monitor IGF-1 and glucose, since GH-axis stimulation can affect glucose metabolism. For how it compares with the GHRH analogue in section 2, see CJC-1295 vs tesamorelin for visceral fat.

6. Kisspeptin — For the Testosterone Signaling Axis

Targets: LH and testosterone signaling, reproductive axis

Kisspeptin is the hypothalamic signal that drives GnRH release, which in turn drives the pituitary's LH output and the testes' testosterone production. In a small human physiology study in healthy men, intravenous kisspeptin-10 raised LH and increased LH pulse frequency, consistent with stimulation of GnRH release. It is not FDA-approved, and there are no long-term outcome trials, so it is best understood as an investigational tool for men whose low testosterone is of central (hypothalamic) origin. A full men's hormone panel is the starting point for that distinction.

7. Semaglutide and Tirzepatide — For Weight and Metabolic Risk

Targets: Body weight, visceral fat, insulin resistance, cardiovascular risk

Midlife weight gain, insulin resistance and low testosterone tend to travel together. Semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist) are peptide-based prescription drugs with the strongest evidence of anything on this page. In the STEP 1 trial, semaglutide produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo; in SURMOUNT-1, tirzepatide produced mean reductions of 15–21% across dose arms at 72 weeks versus 3.1% with placebo. The SELECT trial found that semaglutide reduced major cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease. Part of the weight lost is lean mass, which is one reason prescribers pair these drugs with resistance training and adequate protein.

8. GHK-Cu — For Skin and Tissue Repair

Targets: Skin quality, wound healing, connective-tissue remodeling

GHK-Cu is a naturally occurring copper-binding tripeptide whose plasma levels decline with age. Laboratory and gene-expression research shows it influences genes involved in tissue remodeling, collagen synthesis and antioxidant defense, and it has been studied in topical cosmetic formulations. Evidence for injectable use in humans is thin: most data are in vitro or animal. GHK-Cu is not FDA-approved and is one of the substances scheduled for a second PCAC meeting before the end of February 2027.

9. MOTS-c — For Metabolic Resilience

Targets: Insulin sensitivity, metabolic flexibility, physical capacity with aging

MOTS-c is a peptide encoded in mitochondrial DNA. In mice, it acted on skeletal muscle through AMPK signaling and prevented diet-induced obesity and insulin resistance. No randomized human trials of MOTS-c treatment have been published, so its effects in men are not established. At the July 2026 meeting, the PCAC voted 7–5 (2 abstentions) to recommend adding MOTS-c to the 503A Bulks List; the vote is advisory and rulemaking is pending.

10. Thymosin Alpha-1 — For Immune Resilience

Targets: Immune function, T-cell health, inflammation, infection resistance

Men over 40 face a gradual but significant decline in immune function — technically called immune senescence — that leaves them more vulnerable to infections, slower to clear pathogens, and increasingly prone to chronic low-grade inflammation. Thymosin Alpha-1 directly addresses this by stimulating T-cell maturation and function, enhancing natural killer (NK) cell activity, and modulating inflammatory cytokine production. Clinically, it is used in over 35 countries as a pharmaceutical immunomodulator (Zadaxin), approved for conditions from chronic hepatitis to cancer adjuvant therapy. For anti-aging and health maintenance purposes, Thymosin Alpha-1 helps maintain the immune competence of youth — essential not just for avoiding illness, but for preventing the chronic inflammation that drives cardiovascular disease, neurodegeneration, and cancer as men age.

40 Is Not a Ceiling — It’s a Starting Point

The hormonal and physiological changes of midlife are real, but they’re not inevitable or irreversible. Peptide therapy offers men over 40 a scientifically grounded, medically supervised set of tools for maintaining peak function — in the gym, at work, in their relationships, and in their long-term health. Start with a comprehensive hormone and metabolic panel, work with a qualified provider to identify your specific deficits, and design a protocol tailored to your goals. Visit newtropin.com to explore provider resources, vetted pharmacy partners, and everything you need to take your next decade of health seriously.

Medical Disclaimer This content is for informational purposes only. Always consult a qualified healthcare provider before starting any peptide or hormone therapy.

Related reading: Testagen peptide bioregulator profile

Related reading: custom-compounded peptide therapy

Related reading: Newtropin's men's hormone optimization program

Frequently Asked Questions

What are the best peptides for men over 50?

The same physiology applies after 50, but the evidence bar matters more as cardiovascular and cancer risk rise. Tesamorelin and the GLP-1 medicines have the strongest human trial data for fat and metabolic goals; GH-axis peptides such as sermorelin are studied mainly for restoring GH and IGF-1. Any choice should start with labs and a review of history by a licensed prescriber.

What is the best peptide stack for men over 40?

There is no clinically proven "best" stack: almost no combinations have been tested together in published human trials. The most commonly prescribed pairing is a GHRH analogue with a ghrelin-receptor agonist such as CJC-1295 with ipamorelin. Our guide to peptide stacks for weight loss and muscle gain compares the common combinations and the evidence behind each.

Are peptides safe for men over 40?

Safety depends on the specific compound, its source and the patient. FDA-approved drugs such as tesamorelin, semaglutide and tirzepatide have known side-effect profiles from large trials, while many research peptides have little long-term human safety data. GH-axis peptides can raise IGF-1 and affect glucose, so they need baseline and follow-up labs and are generally avoided in men with active cancer.

Do peptides raise testosterone?

Most peptides on this list do not raise testosterone directly. Kisspeptin is the exception in research: in small studies of healthy men it increased LH, the pituitary signal that drives testosterone production. Men with symptoms of low testosterone should have it confirmed with labs, since low testosterone has several possible causes and treatments.

Are peptides legal?

FDA-approved peptide drugs (tesamorelin, bremelanotide, semaglutide, tirzepatide) are legal by prescription. Many other peptides are not FDA-approved and are not on the 503A Bulks List; the July 2026 PCAC votes in favor of BPC-157, TB-500, MOTS-c and others are advisory until FDA completes rulemaking. The FDA Peptide Status Tracker shows the current status of each compound.

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
2. Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed
3. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
4. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed
5. George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. PubMed
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
8. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
9. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PubMed
10. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed